Background: Recently, it has been demonstrated that immunostimulatory DNA sequences (ISS) containing CpG motifs prevent the development of allergic airway responses in murine models of disease. However, few studies have addressed the issue of whether these agents will reverse established Tm(H)2-driven allergic airway responses.

Objective: The aim of this study was to determine whether intradermal delivery of an immunogenic protein of ragweed pollen linked to an immunostimulatory DNA sequence could reverse an established allergic response in the mouse lung.

Methods: Mice sensitized and challenged with ragweed pollen extract were treated intradermally twice at 1-week intervals with an ISS chemically linked to Amb a 1 (Amb a 1-ISS). One week after the Amb a 1-ISS treatment, mice were rechallenged intratracheally with ragweed extract, and airway responses were assessed.

Results: Amb a 1-ISS treatment of ragweed-sensitized and ragweed-challenged mice significantly reversed allergen-induced airway hyperresponsiveness and suppressed the total number of eosinophils in bronchoalveolar lavage fluid. The inhibitory effect of Amb a 1-ISS was associated with a marked increase in IFN-gamma levels by Amb a 1-stimulated splenocytes and a shift in the antibody profile from a T(H)2-directed IgG1 response to a T(H)1-directed IgG2a response. Interestingly, the inhibitory effect of Amb a 1-ISS on allergen-driven airway hyperresponsiveness was independent of suppression of T(H)2 cytokine production.

Conclusion: These results demonstrate that intradermal delivery of allergen-specific DNA conjugates can reverse established allergic responses in the murine lung, supporting their potential use in the treatment of human asthma.

Download full-text PDF

Source
http://dx.doi.org/10.1067/mai.2002.122156DOI Listing

Publication Analysis

Top Keywords

amb 1-iss
20
reverse established
16
airway hyperresponsiveness
12
amb
8
immunostimulatory dna
8
allergic airway
8
airway responses
8
responses murine
8
intradermal delivery
8
ragweed pollen
8

Similar Publications

Gateways to clinical trials.

Methods Find Exp Clin Pharmacol

June 2007

Prous Science, S.A., PO Box 540,08080 Barcelona, Spain.

101M, 12B75; ABT-869, Agomelatine, Alvocidib hydrochloride, Amb a 1 ISS-1018, AMG-386, Andolast, AP-23573, Arsenic trioxide, ATI-7505; BAY-68-4986, Berberine chloride, BNP-1350, BrachySil, Brostallicin hydrochloride; Caldaret hydrate, Cancer vaccine, Cediranib, CHAMPION everolimus-eluting coronary stent, CP-751871; D-4F, Degarelix acetate, Dofequidar fumarate; Ecogramostim, Enzastaurin hydrochloride, Etaracizumab, Everolimus; Fluticasone furoate; Glucarpidase; Hochuekki-to, Human papillomavirus vaccine; Icatibant acetate, INO-1001, Interleukin-21, Irofulven, ISIS-301012, Ixabepilone; KRN-951; Lacosamide; Mecasermin, Mecasermin rinfabate, Mepolizumab, Mesna disulfide, m-NO-ASA; Nematode anticoagulant protein c2, Nilotinib, Nolatrexed dihydrochloride; O6-Benzylguanine; Pemetrexed disodium, Perifosine, Pertuzumab, Plitidepsin, Prasterone, PRO-2000/5, PX-12, Pyridoxal phosphate; Recombinant human soluble thrombomodulin, Retapamulin, Rinfabate, Rubitecan; Seliciclib, SR-271425, STA-4783; T- 2000, Telatinib, Temsirolimus, Terameprocol, Teverelix, Ticagrelor, Tipelukast, Tirapazamine; Uracil; Valspodar, Vatalanib succinate, Velimogene aliplasmid, Vitespen, Volociximab; XL-184.

View Article and Find Full Text PDF

Gateways to clinical trials.

Methods Find Exp Clin Pharmacol

November 2006

Prous Science, Barcelona, Spain.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.

View Article and Find Full Text PDF

Modified recombinant allergens for safer immunotherapy.

Inflamm Allergy Drug Targets

January 2006

Department of Molecular Biology, University of Salzburg, A-5020 Salzburg, Austria.

Molecular cloning and recombinant production of allergens offered new perspectives for the increasing problem of allergies. A variety of preparations are being developed aiming to increase safety and improve efficacy of specific immunotherapy. Recombinant-based approaches are mostly focused on genetic modification of allergens to produce molecules with reduced allergenic activity and conserved antigenicity, i.

View Article and Find Full Text PDF

Background: Recently, it has been demonstrated that immunostimulatory DNA sequences (ISS) containing CpG motifs prevent the development of allergic airway responses in murine models of disease. However, few studies have addressed the issue of whether these agents will reverse established Tm(H)2-driven allergic airway responses.

Objective: The aim of this study was to determine whether intradermal delivery of an immunogenic protein of ragweed pollen linked to an immunostimulatory DNA sequence could reverse an established allergic response in the mouse lung.

View Article and Find Full Text PDF

Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity.

J Allergy Clin Immunol

July 2000

Department of Medicine and The Sam and Rose Stein Institute for Research on Aging, and the Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, USA.

Background: Allergen immunotherapy is inconvenient and associated with the risk of anaphylaxis. Efforts to improve the safety of immunotherapy by means of chemical modification of allergens have not been successful because it greatly reduced their antigenicity. Recently, immunostimulatory DNA sequences (ISS or CpG motifs) have been shown to act as strong T(H)1 response-inducing adjuvants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!